FDA requires rare vision-loss warning for GLP-1 drugs
The U.S. Food and Drug Administration is requiring makers of GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to add warnings about a potentially increased risk of a rare eye condition that can cause permanent vision loss.
The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when reduced blood flow damages the optic nerve. Sometimes called an “eye stroke,” it can cause painless, abrupt vision loss, blurred vision, blind spots or distorted colors, often in one eye. The FDA advised patients who experience visual changes while taking a GLP-1 drug to contact a health care professional immediately.
The agency said NAION has been reported with all currently marketed GLP-1 receptor agonists. Its review included adverse-event reports and clinical studies involving more than 125,000 patients. The FDA found about six cases annually per 100,000 people …